DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01373216

Executive

CompletedPhase 3

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

EXEnatide in Patients Undergoing Coronary Artery Bypass Grafting for Improved glUcose conTrol and hemodynamIc ValuEs

Asset

Exenatide

Intravenous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

38

actual

Study population

Cardiovascular disease, Heart failure, Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Cardiac function - echocardiographic parameters

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01373216
Org study IDH8O-CY-O027

Timeline

Milestones

Study first posted2011-06-14estimated
Last update posted2016-02-02estimated
Study start2011-06 (month precision)
Primary completion2014-05actual (month precision)
Study completion2014-12actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Cardiovascular diseaseHeart failurePerioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•elective coronary artery bypass grafting operation (CABG)
•decreased left ventricular (LV) systolic function (EF LV ≤ 50%)
•Age 18 to 85
•Signed informed consent
•Females with childbearing potential have to use appropriate contraceptive measures during the whole study period and 6 months after terminating exenatide infusion (hormonal contraception or double-barrier contraception for both partners)

Exclusion criteria

•allergy to exenatide
•allergy to insulin
•mental incapacity or language barrier
•use of incretin-based therapies <3 months before inclusion in the study
•diabetic ketoacidosis
•established autonomic neuropathy
•history of acute pancreatitis or severe disease of digestive tract
•renal failure (preoperative creatinine ≥ 180 umol/l)
•liver failure (coagulation times more than 1.5 times higher without use of anticoagulants)
•cardiac surgical procedure on valve, thoracic aorta or MAZE procedure
•pregnancy and lactation

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
1
Other (unclassified)
1

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Number of participants with adverse effects

Time frame:90 days after administration of exenatide

Treatment-emergent AEs (any)

event count, event

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Cardiac function - echocardiographic parameters

Time frame:90 days after administration of exenatide

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.